Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients

International Journal of Oncology

Volumn 35, Issue 6, 2009, Pages 1369-1376

  Vazquez Martin, Alejandro ^a   Fernandez Real, Jose Manuel ^a   Oliveras Ferraros, Cristina ^a   Navarrete, Jose Maria ^a   Martin Castillo, Begoña ^a   Del Barco, Sonia ^a   Brunet, Joan ^a   Menendez, Javier A ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Breast cancer; C75; Fatty acid synthase; HER2; HER2 extracellular domain; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID SYNTHASE; TUMOR MARKER;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME ACTIVITY; FASN GENE; GENE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; BLOOD; BREAST TUMOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; METABOLISM; PATHOLOGY; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACID SYNTHETASE COMPLEX; FEMALE; HUMANS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 73949094795     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000455     Document Type: Article

References (48)

1. Isola J, Chu L, DeVries S, Matsumura K, Chew K, Ljung BM and Waldman FM: Genetic alterations in ERBB2-amplified breast carcinomas. Clin Cancer Res 5: 4140-4145, 1999.
2. Pegram MD, Konecny G and Slamon DJ: The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 103: 57-75, 2000.
3. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
4. Zhang DH, Salto-Tellez M, Do E, Putti TC and Koay ESC: Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 34: 362-368, 2003.
5. Nahta R, Yu D, Hung MC, Hortobagyi GN and Esteva FJ: Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3: 269-280, 2006.
6. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX and Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435-2446, 1995.
7. Alaoui-Jamali MA, Paterson J, Al Moustafa AE and Yen L: The role of ErbB2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. Biochem Cell Biol 75: 315-325, 1997.
8. Yarden Y: Biology of HER2 and its importance in breast cancer. Oncology 61: 1-13, 2001.
9. Marmor MD, Skaria KB and Yarden Y: Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58: 903-913, 2004.
10. Citri A and Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516, 2006.
11. Wilson KS, Roberts H, Leek R, Harris AL and Geradts J: Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am J Pathol 161: 1171-1185, 2002.
12. Mackay A, Jones C, Dexter T, Silva RL, Bulmer K, Jones A, Simpson P, Harris RA, Jat PS, Neville AM, Reis LF, Lakhani S and O'Hare MJ: cDNA microarray analysis of genes associated with ErbB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 22: 2680-2688, 2003.
13. White SL, Gharbi S, Bertani MF, Chan HL, Waterfield MD and Timms JF: Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression. Br J Cancer 90: 173-181, 2004.
14. Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK and Koay ES: Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neupositive breast cancer. Mol Cell Proteomics 4: 1686-1696, 2005.
15. Menendez JA, Lupu R and Colomer R: Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer. Drug News Perspect 18: 375-385, 2005.
16. Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7: 763-777, 2007.
17. Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP and Chinnaiyan AM: Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 63: 132-139, 2003.
18. Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R and Lupu R: Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. Int J Oncol 24: 1369-1383, 2004.
19. Menendez JA, Mehmi I, Verma VA, Teng PK and Lupu R: Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Mol Carcinog 41: 164-178, 2004.
20. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R and Lupu R: Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 101: 10715-10720, 2004.
21. Alli PM, Pinn ML, Jaffee EM, McFadden JM and Kuhajda FP: Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 24: 39-46, 2005.
22. Menendez JA, Vellon L and Lupu R: Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/ neu (erbB-2) oncogene. Ann Oncol 16: 1253-1267, 2005.
23. Puig T, Vázquez-Martín A, Relat J, Pétriz J, Menéndez JA, Porta R, Casals G, Marrero PF, Haro D, Brunet J and Colomer R: Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Cancer Res Treat 109: 471-479, 2008.
24. Vazquez-Martin A, Colomer R, Brunet J, Lupu R and Menendez JA: Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif 41: 59-85, 2008.
25. Wang Y, Kuhajda FP, Li JN, Pizer ES, Han WF, Sokoll LJ and Chan DW: Fatty acid Synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients. Cancer Lett 167: 99-104, 2001.
26. Wang Y, Kuhajda FP, Sokoll LJ and Chan DW: Two-site ELISA for the quantitative determination of fatty acid synthase. Clin Chim Acta 304: 107-115, 2001.
27. Wang YY, Kuhajda FP, Cheng P, Chee WY, Li T, Helzlsouer KJ, Sokoll LJ and Chan DW: A new model ELISA, based on two monoclonal antibodies, for quantification of fatty acid Synthase. J Immunoassay Immunochem 23: 279-292, 2002.
28. Wang YY, Kuhajda FP, Li J, Finch TT, Cheng P, Koh C, Li T, Sokoll LJ and Chan DW: Fatty acid synthase as a tumor marker: its extracellular expression in human breast cancer. J Exp Ther Oncol 4: 101-110, 2004.
29. Oliveras-Ferraros C, Vazquez-Martin A, Fernández-Real JM and Menendez JA: AMPK-sensed cellular energy state regulates the release of extracellular Fatty Acid Synthase. Biochem Biophys Res Commun 378: 488-493, 2009.
30. Menendez JA, Vazquez-Martin A, Ortega FJ and Fernandez-Real JM: Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer. Clin Chem 55: 425-438, 2009.
31. Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massutí B, Cortés-Funes H and Lloveras B: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6: 2356-2362, 2000.
32. Hudelist G, Köstler WJ, Attems J, Czerwenka K, Müller R, Manavi M, Steger GG, Kubista E, Zielinski CC and Singer CF: Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer 89: 983-991, 2003.
33. Köstler WJ, Schwab B, Singer CF, Neumann R, Rücklinger E, Brodowicz T, Tomek S, Niedermayr M, Hejna M, Steger GG, Krainer M, Wiltschke C and Zielinski CC: Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 10: 1618-1624, 2004.
34. Colomer R, Llombart-Cussac A, Lloveras B, Ramos M, Mayordomo JI, Fernández R, Tusquets I, Gil M, Barnadas A, Constenla M, Gilabert M and Alba E: High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study. Cancer 110: 2178-2185, 2007.
35. Fornier MN, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L and Hudis C: Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 16: 234-239, 2005.
36. Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D and Ghani F: Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 7: R436-R443, 2005.
37. Ali SM, Carney WP, Esteva FJ, Fornier M, Harris L, Köstler WJ, Lotz JP, Luftner D, Pichon MF, Lipton A and Serum HER-2/ neu Study Group: Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 113: 1294-1301, 2008.
38. Menendez JA, Vazquez-Martin A, Colomer R, Brunet J, Carrasco-Pancorbo A, Garcia-Villalba R, Fernandez-Gutierrez A and Segura-Carretero A: Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells. BMC Cancer 7: 80, 2007.
39. Vazquez-Martin A, Oliveras-Ferraros C, Colomer R, Brunet J and Menendez JA: Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. Ann Oncol 19: 1097-1109, 2008.
40. Nagy P, Vereb G, Sebestyén Z, Horváth G, Lockett SJ, Damjanovich S, Park JW, Jovin TM and Szöllosi J: Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J Cell Sci 115: 4251-4262, 2002.
41. Menendez JA, Vellon L and Lupu R: Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Med Hypotheses 64: 997-1001, 2005.
42. Mocanu MM, Fazekas Z, Petrás M, Nagy P, Sebestyén Z, Isola J, Tímár J, Park JW, Vereb G and Szöllosi J: Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. Cancer Lett 227: 201-212, 2005.
43. Sottocornola E, Misasi R, Mattei V, Ciarlo L, Gradini R, Garofalo T, Berra B, Colombo I and Sorice M: Role of gangliosides in the association of ErbB2 with lipid rafts in mammary epithelial HC11 cells. FEBS J 273: 1821-1830, 2006.
44. Swinnen JV, Van Veldhoven PP, Timmermans L, De Schrijver E, Brusselmans K, Vanderhoydonc F, Van de Sande T, Heemers H, Heyns W and Verhoeven G: Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 302: 898-903, 2003.
45. Coleman DT, Bigelow R and Cardelli JA: Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation. Mol Cancer Ther 8: 214-224, 2009.
46. Lombardo CR, Consler TG and Kassel DB: In vitro phosphorylation of the epidermal growth factor receptor autophosphorylation domain by c-src: identification of phosphorylation sites and c-src SH2 domain binding sites. Biochemistry 34: 16456-16466, 1995.
47. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J and Baselga J: Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744-4749, 2001.
48. Vazquez-Martin A, Colomer R, Brunet J and Menendez JA: Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin) by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Int J Oncol 31: 769-776, 2007.